142 related articles for article (PubMed ID: 24115455)
1. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.
Roodbeen R; Paaske B; Jiang L; Jensen JK; Christensen A; Nielsen JT; Huang M; Mulder FA; Nielsen NC; Andreasen PA; Jensen KJ
Chembiochem; 2013 Nov; 14(16):2179-88. PubMed ID: 24115455
[TBL] [Abstract][Full Text] [Related]
2. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
3. The binding mechanism of a peptidic cyclic serine protease inhibitor.
Jiang L; Svane AS; Sørensen HP; Jensen JK; Hosseini M; Chen Z; Weydert C; Nielsen JT; Christensen A; Yuan C; Jensen KJ; Nielsen NC; Malmendal A; Huang M; Andreasen PA
J Mol Biol; 2011 Sep; 412(2):235-50. PubMed ID: 21802428
[TBL] [Abstract][Full Text] [Related]
4. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.
Jiang L; Oldenburg E; Kromann-Hansen T; Xu P; Jensen JK; Andreasen PA; Huang M
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2017-2023. PubMed ID: 29959058
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
[TBL] [Abstract][Full Text] [Related]
6. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.
Hosseini M; Jiang L; Sørensen HP; Jensen JK; Christensen A; Fogh S; Yuan C; Andersen LM; Huang M; Andreasen PA; Jensen KJ
Mol Pharmacol; 2011 Oct; 80(4):585-97. PubMed ID: 21719463
[TBL] [Abstract][Full Text] [Related]
8. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases.
Xue G; Xie X; Zhou Y; Yuan C; Huang M; Jiang L
Biosci Biotechnol Biochem; 2020 Jun; 84(6):1153-1159. PubMed ID: 32019421
[TBL] [Abstract][Full Text] [Related]
9. Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids.
Chen S; Gfeller D; Buth SA; Michielin O; Leiman PG; Heinis C
Chembiochem; 2013 Jul; 14(11):1316-22. PubMed ID: 23828687
[TBL] [Abstract][Full Text] [Related]
10. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
[TBL] [Abstract][Full Text] [Related]
11. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
12. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.
Sørensen HP; Xu P; Jiang L; Kromann-Hansen T; Jensen KJ; Huang M; Andreasen PA
J Mol Biol; 2015 Sep; 427(19):3110-22. PubMed ID: 26281711
[TBL] [Abstract][Full Text] [Related]
13. A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.
Zhao B; Xu P; Jiang L; Paaske B; Kromann-Hansen T; Jensen JK; Sørensen HP; Liu Z; Nielsen JT; Christensen A; Hosseini M; Sørensen KK; Nielsen NC; Jensen KJ; Huang M; Andreasen PA
PLoS One; 2014; 9(12):e115872. PubMed ID: 25545505
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
15. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
16. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
17. Peptide ligands stabilized by small molecules.
Chen S; Bertoldo D; Angelini A; Pojer F; Heinis C
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1602-6. PubMed ID: 24453110
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of the protease domain of urokinase-type plasminogen activator.
Rockway TW; Nienaber V; Giranda VL
Curr Pharm Des; 2002; 8(28):2541-58. PubMed ID: 12369939
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and analysis of novel bicyclic and bifunctional protease inhibitors.
Jaulent AM; Leatherbarrow RJ
Protein Eng Des Sel; 2004 Sep; 17(9):681-7. PubMed ID: 15486024
[TBL] [Abstract][Full Text] [Related]
20. A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue.
Mazzocato Y; Perin S; Morales-Sanfrutos J; Romanyuk Z; Pluda S; Acquasaliente L; Borsato G; De Filippis V; Scarso A; Angelini A
Bioorg Med Chem; 2023 Nov; 95():117499. PubMed ID: 37879145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
